MSB 7.03% $1.33 mesoblast limited

Australian newspaper article, page-160

  1. 15,657 Posts.
    lightbulb Created with Sketch. 5718
    ..... or I guess another way to put it in simple terms - the FDA now agree that all of the previously submitted Remestemcel-L sr-GVHD treatment data you have claimed for years was flawed, isn't actually flawed and subsequently the FDA now believe it's enough for a pediatric approval


    You’ve got enough to get approved for children – go ahead and file, and then consider how to take the product into adults.’’


    Who to believe ....the FDA (USA Regulatory Body) doing an about face or an anonymous HC poster refusing to admit defeat ?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.